# Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)

> **NCT01506414** · PHASE3 · COMPLETED · sponsor: **Ming Hou** · enrollment: 91 (actual)

## Conditions studied

- Purpura
- Idiopathic Thrombocytopenic Purpura

## Interventions

- **DRUG:** rhTPO in combination with Rituximab

## Key facts

- **NCT ID:** NCT01506414
- **Lead sponsor:** Ming Hou
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2013-08
- **Final completion:** 2013-12
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2016-04-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01506414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01506414, "Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01506414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*